08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC, Wellcome Trust, Merck, Cancer Research UK deal

Cancer Research UK’s commercialization and development arm, Cancer Research Technology (CRT), granted Merck worldwide rights to develop and commercialize inhibitors of protein arginine methyltransferase 5 (PRMT5) . The inhibitors were developed by Cancer Therapeutics CRC...
02:24 , Jan 28, 2016 |  BC Extra  |  Company News

Merck, CRT in deal for PRMT5 inhibitors

Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders. The inhibitors were...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Alchemia, Cancer Research Technology deal

Alchemia licensed two preclinical focal adhesion kinase (FAK) inhibitors from Cancer Research Technology. Alchemia will evaluate the compounds in cancer and cancer stem cell models and potentially develop the compounds for undisclosed cancer indications. Cancer...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC (CTx) Pty. Ltd. cancer news

CTx said the Australian government's Cooperative Research Center (CRC) Program will continue to fund CTx for a further six years with a total of A$34 million ($30.5 million). CTx said the focus of its continued...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Clinical News

Bionomics, Cancer Therapeutics CRC preclinical data

In an animal model of melanoma, CTx-0357927 inhibited tumor metastasis in 60% of animals vs. 20% for vehicle-treated controls. CTx-0357927 also inhibited tumor growth vs. controls (p=0.014). Cancer Therapeutics and Bionomics are co-developing the inhibitor...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC, Cancer Research U.K. deal

The research center's commercial arm Cancer Research Technology (CRT) Ltd. exercised an option to sublicense exclusive, worldwide rights to develop and commercialize Cancer Therapeutics' CTx-0294945 and CTx-0294886 . CTx-0294945 is a highly-selective small molecule inhibitor...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Cancer Therapeutics CRC preclinical data

In a mouse model of breast cancer, CTx-0294886 plus Avastin bevacizumab significantly increased median survival time vs. Avastin alone (p=0.02). Additionally, CTx-0294886 plus Avastin inhibited angiogenesis and increased the duration of tumor response vs. Avastin...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Cancer Therapeutics CRC preclinical data

In a mouse model of TNBC, 80 mg/kg oral CTX-0294945 plus Avastin bevacizumab inhibited tumor growth by 88% at day 28 compared to 75% for Avastin alone. At day 28, tumors in mice receiving vehicle...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC, Duke University deal

Cancer Therapeutics received exclusive, worldwide rights to develop and commercialize the university's preclinical lipid metabolizing enzyme inhibitors to treat cancer. Cancer Therapeutics will conduct preclinical development and seek a partner for further development. The university...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC, Novation deal

Cancer Therapeutics CRC Pty. Ltd. , Bundoora, Australia   Novation Pharmaceuticals Inc. , Vancouver, B.C.   Business: Cancer   The partners will combine Novation's Quest drug discovery technology and Cancer Therapeutics' small molecule compound library...